Evidence map›Paper›PMID 24752177›Full record

Trial reportPloS one2014

Change in vitamin d levels occurs early after antiretroviral therapy initiation and depends on treatment regimen in resource-limited settings.

Fiona P Havers, Barbara Detrick, Sandra W Cardoso, Sima Berendes, Javier R Lama, Patcharaphan Sugandhavesa, Noluthando H Mwelase, Thomas B Campbell, Amita Gupta, ACTG A5175 PEARLS and NWCS319 Study Teams

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019
    Guideline
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Observational
  8. Review
  9. Osteoporosis and HIV Infection.Calcified tissue international · 2022
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Bone Loss in HIV Infection.Current treatment options in infectious diseases · 2017
    Article
  15. Bone health in HIV and hepatitis B or C infections.Therapeutic advances in musculoskeletal disease · 2017
    Review
  16. Vitamin D Status and Its Consequences for Health in South Africa.International journal of environmental research and public health · 2016
    Review
  17. Article
  18. HIV infection and osteoporosis.BoneKEy reports · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 7 countries.

Fiona P HaversJohns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Barbara DetrickJohns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Sandra W CardosoEvandro Chagas Clinical Research Institute (IPEC), FIOCRUZ, Rio de Janeiro, Brazil.
Sima BerendesCollege of Medicine-Johns Hopkins University Research Project, Blantyre, Malawi; Liverpool School of Tropical Medicine, Liverpool, United Kingdom.
Javier R LamaAsociacion Civil Impacta Salud y Educacion, Lima, Peru.
Patcharaphan SugandhavesaChiang Mai University, Chiang Mai, Thailand.
Noluthando H MwelaseUniversity of Witswatersrand, Johannesburg, South Africa.
Thomas B CampbellUniversity of Colorado Denver, Aurora, Colorado, United States of America.
Amita GuptaJohns Hopkins University School of Medicine, Baltimore, Maryland, United States of America; Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
ACTG A5175 PEARLS and NWCS319 Study Teams
Johns Hopkins Medicine · USAsociación Civil Impacta Salud y Educación · PEChiang Mai University · THFundação Oswaldo Cruz · BRUniversity of Colorado Denver · USUniversity of Malawi · MWUniversity of the Witwatersrand · ZA

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
AIDS Clinical Trials Group NetworkU01AI068636 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI KURITZKES, DANIEL R. · 2006 to 2010
$147.1M
UCSD Department of Medicine HIV/AIDS Clinical Trials UnitUM1AI069432 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TIMOTHY J. WILKIN · 2012 to 2026
$50.4M
Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplicationUM1AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI REES, HELEN, SANNE, IAN MATTHIAS · 2012 to 2025
$31.8M
Thailand HIV/AIDS and Infectious Disease Clinical Trials Unit (THAI CTU)UM1AI069399 · NIAID · CHIANG MAI UNIVERSITY · PI Kiat Ruxrungtham, Khuanchai Supparatpinyo · 2012 to 2026
$25.0M
RESEARCH TRAINING IN MICROBIAL DISEASEST32AI007291 · NIAID · JOHNS HOPKINS UNIVERSITY · PI JOEL N BLANKSON, Sara Elizabeth Cosgrove · 1986 to 2026
$9.1M
Colorado AIDS Clinical Trials UnitU01AI069450 · NIAID · UNIVERSITY OF COLORADO DENVER · PI CAMPBELL, THOMAS B. · 2007 to 2011
$8.3M
PREVENTION MATERNAL TO INFANT HIV TRANSMISSION IN INDIAR01AI045462 · NIAID · JOHNS HOPKINS UNIVERSITY · PI BOLLINGER, ROBERT C · 1999 to 2005
$5.8M
Colorado AIDS Clinical Trials UnitUM1AI069450 · NIAID · UNIVERSITY OF COLORADO DENVER · PI CAMPBELL, THOMAS B. · 2012 to 2013
$2.6M
NIAID NIH HHS AI069450NIAID NIH HHS AI68636NIAID NIH HHS R01 AI045462NIAID NIH HHS R01 AI45462NIAID NIH HHS T32 AI007291NIAID NIH HHS U01 AI068636NIAID NIH HHS U01 AI069450NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069399NIAID NIH HHS UM1 AI069432NIAID NIH HHS UM1 AI069450NIAID NIH HHS UM1 AI069463
6 · The paper itself

Abstract

STUDY

backgroundVitamin D has wide-ranging effects on the immune system, and studies suggest that low serum vitamin D levels are associated with worse clinical outcomes in HIV. Recent studies have identified an interaction between antiretrovirals used to treat HIV and reduced serum vitamin D levels, but these studies have been done in North American and European populations.

methodsUsing a prospective cohort study design nested in a multinational clinical trial, we examined the effect of three combination antiretroviral (cART) regimens on serum vitamin D levels in 270 cART-naïve, HIV-infected adults in nine diverse countries, (Brazil, Haiti, Peru, Thailand, India, Malawi, South Africa, Zimbabwe and the United States). We evaluated the change between baseline serum vitamin D levels and vitamin D levels 24 and 48 weeks after cART initiation.

resultsSerum vitamin D levels decreased significantly from baseline to 24 weeks among those randomized to efavirenz/lamivudine/zidovudine (mean change: -7.94 [95% Confidence Interval (CI) -10.42, -5.54] ng/ml) and efavirenz/emtricitabine/tenofovir-DF (mean change: -6.66 [95% CI -9.40, -3.92] ng/ml) when compared to those randomized to atazanavir/emtricitabine/didanosine-EC (mean change: -2.29 [95% CI -4.83, 0.25] ng/ml). Vitamin D levels did not change significantly between week 24 and 48. Other factors that significantly affected serum vitamin D change included country (p<0.001), season (p<0.001) and baseline vitamin D level (p<0.001).

conclusionEfavirenz-containing cART regimens adversely affected vitamin D levels in patients from economically, geographically and racially diverse resource-limited settings. This effect was most pronounced early after cART initiation. Research is needed to define the role of Vitamin D supplementation in HIV care.

Indexed as

Antiretroviral Therapy, Highly ActiveDeveloping CountriesHealth ResourcesAdultAnti-Retroviral AgentsBlack or African AmericanFemaleHIV InfectionsHumansMaleRegression AnalysisTreatment OutcomeVitamin DAnti-Retroviral AgentsVitamin D

Identifiers

PMID24752177
PMCPMC3994063
OpenAlexW2124136646

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.